Los Angeles– Sensydia, a medical technology firm developing non-invasive cardiac assessment tools, has appointed industry veteran Rusty Page as its new President and Chief Operating Officer. The move strengthens the company’s leadership as it prepares for regulatory submission and commercial launch of its flagship Cardiac Performance System (CPS™).
Page joins Sensydia from Neuronetics, Inc., where he served as Senior Vice President and Chief Information & Operations Officer. He brings more than 20 years of experience in medical devices and diagnostics, with a focus on operational growth and commercialization.
At Sensydia, Page will oversee operations, quality, IT, and business infrastructure—key areas as the company scales up to bring its CPS platform to market. The CPS is a non-invasive system designed to offer advanced cardiac function monitoring without the need for catheterization or imaging.
“Rusty’s track record guiding early-stage medical device companies from development to commercialization makes him an ideal fit for Sensydia,” said Anthony Arnold, CEO of Sensydia. “His strategic and operational leadership will be vital as we advance CPS through regulatory review and into clinical use.”
Before Neuronetics, Page held multiple leadership roles in the medtech sector, including Vice President of Operations and Quality and General Manager at Bioness, where he helped grow the company through several product launches leading up to its acquisition by Bioventus in 2021.
“I’m thrilled to join Sensydia at such a pivotal time,” Page said. “The potential of the Cardiac Performance System to reshape cardiovascular care is incredibly compelling, and I look forward to supporting the team as we build toward market readiness.”
Page brings deep expertise across manufacturing, global supply chain, regulatory compliance, and quality systems, including those governed by the FDA and international regulatory bodies.
